|
| |
XencorSince 1997, Xencor has built the most powerful protein engineering technology platform in the biotechnology industry. Its versatility is evidenced by our success in developing two classes of superior protein drug candidates: XmAb™ antibody therapeutics and XPro™ protein therapeutics. Because we can engineer the affinity and specificity of protein-protein interactions, we are also generating entirely new therapeutic mechanisms of action.In collaboration with our partners—including leading biotechnology company Genentech and pharmaceutical company Eli Lilly—we are selectively designing next-generation protein drug candidates with improved selectivity, efficacy and safety. Our internal pipeline of antibodies for cancer and protein therapeutics for inflammation and autoimmune disease address well understood and validated targets with potent new molecules. More than 40 talented scientists and the 8 industry veterans who make up our management team are working diligently to bring these drugs to the clinic and to deliver on the promise of protein-based medicines.
| Contact Details: |
| 111 West Lemon Avenue |
| Monrovia |
| California |
| 91016 |
| United States of America |
| Tel: | 626-305-5900 |
| Fax: | 626-305-0350 |
| Email: | info@xencor.com |
| WWW: | www.xencor.com/
|
|
Loading...
|
Recent Publications by Xencor: |  |
The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates.
CD19, a B cell-restricted receptor critical for B-cell development, is... | 16th May, 2009
| Xencor,
| Blood. 2009 Apr 16;113(16):3735-43. Epub 2008 Dec 24.
DOI Direct Link |
Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
CD19 is a pan B-cell surface receptor expressed from pro-B-cell... | 17th December, 2008
| Xencor, Inc, Monrovia, California 91016, USA.
| Cancer Res. 2008 Oct 1;68(19):8049-57.
DOI Direct Link |
Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies.
The humoral immune response requires antigen-specific B cell activation... | 17th December, 2008
| Xencor, Inc., 111 W. Lemon Avenue, Monrovia, CA 91016, USA.
| Mol Immunol. 2008 Sep;45(15):3926-33. Epub 2008 Aug 8.
DOI Direct Link |
Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells.
The contribution of Fc-mediated effector functions to the therapeutic... | 23rd October, 2008
| Xencor, 111 West Lemon Avenue, Monrovia, CA 91016, USA.
| Mol Cancer Ther. 2008 Aug;7(8):2517-27.
DOI Direct Link |
Phenomena of insulin peak fronting in size exclusion chromatography and strategies to reduce fronting.
Insulin peak fronting in size exclusion chromatography (SEC) results in... | 22nd July, 2008
| Xencor Inc., 111 West Lemon Avenue, Monrovia, CA 91016, USA.
| J Chromatogr A. 2008 May 23;1192(1):121-9. Epub 2008 Mar 22.
DOI Direct Link |
→View more Xencor research publications. |
Press Releases on Xencor:
|
 |
| Reportlinker Adds Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline Insight |
5th November, 2009 |
Reportlinker |
NEW YORK, Nov. 5 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline
|
| Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment |
26th October, 2009 |
Reportlinker |
-- A focus on "engineered" antibodies
Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment reviews the broad drug development effort that is focused on bringing
|
| MichBio Announces Annual Business Meeting Keynote and Pre-Meeting Workshop |
17th March, 2009 |
MichBio |
ANN ARBOR, Mich., March 17 /PRNewswire-USNewswire/ -- MichBio, the association for Michigan biosciences, will host Harry Stylli, Ph.D., president and CEO of San Diego, CA-based Sequenom, Inc. as the
|
| MedPredict Publishes Two New Reports Providing Expert Analysis of Malignant Hematology Drug Development |
23rd January, 2009 |
MedPredict |
SCOTTSDALE, Ariz., Jan. 23 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published two new reports providing
|
| BioSeeker launches new report "New Targets and Drug Discovery
|
1st January, 1970 |
Bioseeker |
BioSeeker launches new report "New Targets and Drug Discovery Platforms in Antifungal R&D"
According to the Antifungal
Work Group at NIH
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 429 times since April 2007, the link to the organisation's website has been followed 63 times Recent Search Terms used to find this page: xencor Inc in Monrovia California | xencor logo | . Search for more companies in Monrovia Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Xencor |
